# PACE (NCT01584258)

> Prostate Advances in Comparative Evidence

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01584258
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Royal Marsden NHS Foundation Trust
- Conditions: Prostate Cancer
- Interventions: Prostatectomy; Conventionally Fractionated Prostate Radiotherapy; Prostate SBRT
- Enrollment: 2205
- Primary outcome: PACE-B and PACE-C: Freedom from biochemical or clinical failure
- Primary outcome: PACE-A: Co-primary patient reported outcomes of urinary incontinence and bowel bother

## Questions raised in the commentary

_Automated, Oct 29, 2026. Not an Erudio report: no source links. Not medical advice._

The commentary discusses PACE-A’s comparison of SBRT with prostatectomy and how to place it alongside other prostate radiotherapy trials. Topics include cancer-control measures, patient-reported urinary, sexual and bowel outcomes, treatment choice, and shared decision-making. A speaker questions whether continence was an appropriate co-primary endpoint given the different effects of surgery and radiotherapy. Discussion also addresses the change in primary endpoint, the trial’s shortfall from its planned enrollment, and whether the available evidence can establish equivalence.

## Indexed commentary on PACE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 130
- Podcasts: 5
- YouTube: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=pace-nct01584258

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01584258", "email": "<work email>"}; the inbox owner confirms by the emailed link.